Clover Corporation Limited
ABN 85 003 622 866

ASX ANNOUNCEMENT **22 September 2026**

Clover delivers record FY26 revenue and strong earnings

Results for the year ended 31 July 2026

Clover Corporation Limited (ASX:CLV) has delivered record revenue of $97.4 million for FY26, up 13% on the prior year, together with Net Profit after tax (NPAT) of $10.5 million, up 50%, reflecting continued growth and demand for its newer products and improving operating performance.

- Record revenue of $97.4 million ahead of guidance, up 13% on the prior year
- 2H revenue of $53.3 million (1H $44.1 million) an increase of 10% on the same period prior year
- NPAT of $10.5 million, up 50% on $7.0 million in FY25
- Innovation in new products and demand for ARA powders driving higher margin.
- Improved operating performance at Melody Dairies, including higher production volumes and lower unit costs
- Ecuador crude tuna oil facility continued to provide a secure, competitively priced source of supply
- Continued progress commercialising CholineXcel
- Fully franked final dividend of 1.25 cents per share for FY26

Clover Corporation CEO Peter Davey said:

"FY26 was a strong year for Clover, with record revenue of $97.4 million and NPAT increasing 50% to $10.5 million. Importantly, the improvement was broad based, with a continued focus on diversified earnings. Our result this year reflects the management team's disciplined execution of the core business whilst servicing both existing and new customers."

"The investments we have made in supply chain security and vertical integration are delivering tangible benefits. Melody Dairies achieved higher production volumes and lower unit costs, while our Ecuador operation has become an important source of quality crude oil at competitive costs.

"We have also continued to broaden our market reach and progress our pipeline of new products. Assisting our customers in their product differentiation together with our expanded distribution model, is supporting our ability to reach new customers and markets while continuing to build a more diversified earnings base."

Strategic Developments

The improved revenue and profit margin performance evident in FY26 is a direct result of Clover's strategy to invest in supply chain quality and security, and new product innovations. Key milestones for FY26 included:

- Ongoing commercialisation of Clover's unique flowable powder CholineXcel, most notably the commencement of customer trials and the successful filing of intellectual property, facilitating a broader customer engagement.
- Investment in the development of a strategy to access the USA nutraceutical market through a dedicated resource investigating product options and potential partners.
- Continued investment in product innovation to access new markets and opportunities, with the most notable for FY26 being further diversification into non-allergenic, higher fortification and plant-based DHA powders.
- Continued investment in supply chain quality, diversification and capacity, with the Ecuador tuna-oil extraction operation, increased utilisation of Melody Dairies, and enhancements to our ARA packaging capabilities delivering their intended benefits.

Balance Sheet & Operating Cash Flows

The increase in working capital during FY26 reflects the strategic investment required to source and refine oils and convert them into finished powders to meet customer demand.

The Company continued to balance investment in working capital with debt reduction and capital management initiatives.

During the year, Clover also purchased shares on market to meet anticipated obligations under employee performance rights arrangements, avoiding the need to issue additional shares for those obligations. Capital expenditure requirements remained modest during FY26. The Company continues to assess and invest in growth opportunities where appropriate.

Dividend:

Reflecting the Company's FY26 performance, cash position and expected future capital management requirements, the Board has declared a fully franked final dividend for FY26 of 1.25 cents per share.

Relevant dates for the dividend are as follows:

- Ex-dividend Date: Monday, 20 October 2026
- Record Date: Tuesday, 21 October 2026
- Payment Date: Thursday, 19 November 2026

Outlook:

Clover enters FY2027 with positive momentum supported by continued demand for its nutritional products, the benefits of a vertically integrated high-quality supply chain and further expansion of its distribution network.

Clover anticipates significant investment in the development and ongoing commercialisation of new products.

Based on the current market and global conditions, the Board expects revenue for 1H FY27 to be ahead of the prior corresponding period.

For further information, please contact:

Mr Rupert Harrington – Chairman, Clover Corporation +61 3 8347 5000
Mr Peter Davey – MD & CEO, Clover Corporation +61 3 8347 5000

About Clover Corporation Limited

Clover Corporation is an Australian company listed on the Australian Stock Exchange (ASX:CLV). Clover evolved from being a research and development, manufacturing, and marketing company to one concentrating on forming strategic relationships focused on technology, new product development and commercialisation.

Developed through extensive research and development, our proprietary technologies protect those sensitive oils from oxidation, allowing them to be incorporated into a free flowing powder used in a range of applications. All Clover products reach the highest standards of purity, stability, and performance, allowing customers to maximise and deliver nutrition.

For more information about Clover visit www.clovercorp.com.au